Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 2, 2013, Pages 1268-1279

  Chhablani, Jay ^a   Nieto, Alejandra ^a   Hou, Huiyuan ^a   Wu, Elizabeth C ^b   Freeman, William R ^a   Sailor, Michael J ^a,b   Cheng, Lingyun ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL; DAUNORUBICIN; OXIDIZED POROUS SILICON; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG OVERDOSE; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; EYE EXAMINATION; EYE TOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOLOGY; INFRARED SPECTROSCOPY; LIQUID CHROMATOGRAPHY; LOADING DRUG DOSE; MASS SPECTROMETRY; NICK END LABELING; NONHUMAN; OPHTHALMOSCOPY; PRIORITY JOURNAL; RABBIT; REFLECTOMETRY; SCANNING ELECTRON MICROSCOPY; SUSTAINED DRUG RELEASE; THERMOGRAVIMETRY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BIOCOMPATIBLE MATERIALS; DAUNORUBICIN; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; INTRAVITREAL INJECTIONS; OXIDATION-REDUCTION; POROSITY; RABBITS; RETINA; SILICON COMPOUNDS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; VITREOUS BODY;

EID: 84874988009     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-11172     Document Type: Article

References (31)

1. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol. 1998;43:3-18.
2. Cheng L, Hostetler K, Valiaeva N, et al. Intravitreal crystalline drug delivery for intraocular proliferation diseases. Invest Ophthalmol Vis Sci. 2010;51:474-481.
3. Turgut B, Uyar F, Ustundag B, Celiker U, Akpolat N, Demir T. The impact of tacrolimus on growth factors in experimental proliferative vitreoretinopathy. Retina. 2012;32:232-241.
4. Hou J, Li Y, Zhou Z, et al. Antiproliferative property of hexadecyloxypropyl 9-[2-(phosphonomethoxy) ethyl] guanine (HDP-PMEG) for unwanted ocular proliferation. Mol Vis. 2011; 17:627-637.
5. Wiedemann P, Sorgente N, Bekhor C, Patterson R, Tran T, Ryan SJ. Daunomycin in the treatment of experimental proliferative vitreoretinopathy. Effective doses in vitro and in vivo. Invest Ophthalmol Vis Sci. 1985;26:719-725.
6. Shinohara K, Tanaka M, Sakuma T, Kobayashi Y. Efficacy of daunorubicin encapsulated in liposome for the treatment of proliferative vitreoretinopathy. Ophthalmic Surg Lasers Imaging. 2003;34:299-305.
7. Khawly JA, Saloupis P, Hatchell DL, Machemer R. Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1991; 229:464-467.
8. Wiedemann P, Hilgers RD, Bauer P, Heimann K. Porous silicon particles function as an intravitreal delivery system for daunorubicin. Paper presented at: 8th International Conference Porous Silicon Semiconductors Science and Technology; March 2012; Malaga, Spain.
9. Kumar A, Nainiwal S, Choudhary I, Tewari HK, Verma LK. Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery. Clin Experiment Ophthalmol. 2002;30:348-351.
10. Cheng L, Anglin E, Cunin F, et al. Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle. Br J Ophthalmol. 2008;92: 705-711.
11. Wu EC, Andrew JS, Cheng L, Freeman WR, Pearson L, Sailor MJ. Real-time monitoring of sustained drug release using the optical properties of porous silicon photonic crystal particles. Biomaterials. 2011;32:1957-1966.
12. Nieto A, Hartmann KI, Wu EC, et al. Porous silicon particles function as an intravitreal delivery system for daunorubicin. Paper presented at: 8th International Conference Porous Silicon Semiconductors Science and Technology; March 2012; Malaga, Spain.
13. Wu EC, Andrew JS, Buyanin A, Kinsella JM, Sailor MJ. Suitability of porous silicon microparticles for the long-term delivery of redox-active therapeutics. Chem Commun. 2011; 47:5699-5701.
14. Wu EC, Park J-H, Park J, Segal E, Cunin F, Sailor MJ. Oxidationtriggered release of fluorescent molecules or drugs from mesoporous Si microparticles. ACS Nano. 2008;2:2401-2409.
15. Park JH, Gu L, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ. Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat Mat. 2009;8:331-336.
16. Lehto VP, V̈aḧa-Heikkil̈a K, Paski J, Salonen J. Use of thermoanalytical methods in quantification of drug load in mesoporous silicon microparticles. J Therm Anal Calorim. 2005;80:393-397.
17. Salonen J, Kaukonen AM, Hirvonen J, Lehto VP. Mesoporous silicon in drug delivery applications. J Pharm Sci. 2008;97: 632-653.
18. Maniez-Devos DM, Baurain R, Lesne M, Trouet A. Degradation of doxorubicin and daunorubicin in human and rabbit biological fluids. J Pharm Biomed Anal. 1986;4:353-365.
19. Marney LC, Laha TJ, Baird GS, Rainey PM, Hoofnagle AN. Isopropanol protein precipitation for the analysis of plasma free metanephrines by liquid chromatography-tandem mass spectrometry. Clin Chem. 2008;54:1729-1732.
20. Cheng L, Hostetler KY, Chaidhawangul S, et al. Treatment or prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-O-hexadecylpropanediol-3-phosphoganciclovir. Invest Ophthalmol Vis Sci. 2002;43:515-521.
21. Liang KY, Zeger SL. Longitudinal data-analysis using generalized linear-models. Biometrika. 1986;73:13-22.
22. Anglin EJ, Cheng L, Freeman WR, Sailor MJ. Porous silicon in drug delivery devices and materials. Adv Drug Del Rev. 2008; 60:1266-1277.
23. Wiedemann P, Kirmani M, Santana M, Sorgente N, Ryan SJ. Control of experimental massive periretinal proliferation by daunomycin: dose-response relation. Graefes Arch Clin Exp Ophthalmol. 1983;220:233-235.
24. Santana M, Wiedemann P, Kirmani M, et al. Daunomycin in the treatment of experimental proliferative vitreoretinopathy: retinal toxicity of intravitreal daunomycin in the rabbit. Graefes Arch Clin Exp Ophthalmol. 1984;221:210-213.
25. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855-859.
26. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179-2182.
27. Nan K, Sun S, Li Y, et al. Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-Tenon injection. Br J Ophthalmol. 2010;94:654-658.
28. Kovacs K, Wagley S, Quirk MT, et al. Pharmacokinetic study of vitreous and serum concentrations of triamcinolone acetonide after posterior sub-tenon's injection. Am J Ophthalmol. 2012; 153:939-948.
29. Mietz H, Heimann K. Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal disease. Br J Ophthalmol. 1995;79:874-877.
30. Metaxa AF, Efthimiadou EK, Boukos N, Kordas G. Polysaccharides as a source of advanced materials: Cellulose hollow microspheres for drug delivery in cancer therapy. J Colloid Interface Sci. 2012;384:198-206.
31. Rabowsky JH, Dukes AJ, Lee DA, Leong KW. The use of bioerodible polymers and daunorubicin in glaucoma filtration surgery. Ophthalmology. 1996;103:800-807.